Lung Cancer in India: Why It Is Found Too Late, and What Early Detection Actually Looks Like

Lung cancer in India is found late. Not occasionally — routinely.

At one large tertiary referral centre in north India, 97 per cent of lung cancers were already at stage III or IV by the time they were diagnosed. A series from eastern India found that more than 91 per cent of patients had metastatic disease at first diagnosis. A central India study put stage IV presentation at 57 per cent.

Different hospitals, different states, the same picture. By the time most Indian patients hear the word "cancer," the window in which the disease could have been cured has usually closed.

This is not because Indian doctors are less capable or Indian scanners less sensitive. It is because lung cancer in India behaves differently from lung cancer in the countries whose guidelines we have borrowed — and because the single most common early symptom, a persistent cough, looks identical to something far more common here.

Lung cancer in India is not the disease Western guidelines describe

Almost everything written about lung cancer detection assumes a particular patient: a man in his late sixties or seventies with decades of cigarette smoking behind him. Screening programmes in the United States and United Kingdom are built around exactly that profile.

The Indian patient is frequently someone else entirely:

• They are younger: Indian studies consistently report a median age at diagnosis between 56 and 60 years. Published Indian data suggests the mean age has crept upward over the decades, but remains meaningfully lower than in Western populations.
• Many have never smoked: Across Indian series, never-smokers account for roughly 30 to 54 per cent of lung cancer patients depending on the centre and the population studied. Among Indian women with lung cancer, the great majority have never smoked.
• The histology has shifted: Adenocarcinoma — the type that typically arises in the outer parts of the lung and is more common in never-smokers — has become the dominant form. In one eastern India series, adenocarcinoma accounted for over 76 per cent of non-small cell lung cancers.
• Crucially, Western screening rules do not fit: Researchers applying US and UK screening eligibility criteria to an Indian lung cancer cohort found that fewer than 40 per cent of the ever-smokers in that group would have qualified for screening at all. Nearly half were either under 55 or had never smoked.

Why so many Indian patients are treated for tuberculosis first

This is the most important part of this article, and the part no international guidance addresses.

In India, a cough lasting more than two weeks correctly triggers a suspicion of tuberculosis. That instinct saves lives and it should not change. But lung cancer produces almost exactly the same early picture — cough, weight loss, fatigue, sometimes blood in the sputum, sometimes a shadow on the chest X-ray.

In a TB-endemic country, the common diagnosis is usually the right one. Until it isn't.

An Indian epidemiological study of lung cancer patients found that around 14 per cent had been incorrectly diagnosed and started on anti-tuberculosis treatment, which delayed their cancer diagnosis by several months. Published Indian work has described lung cancer misdiagnosed as sputum-negative tuberculosis as a common medical error. Reviews have noted that most diagnostic misses occur on chest X-ray, which is far less sensitive than CT for detecting and characterising a lung lesion.

The two diseases can also genuinely occur together. A single-centre prospective study in India reported coexistence of TB and non-small cell lung cancer in about 16 per cent of the patients studied — and when both are present, outcomes are worse than with either alone.

The warning signs that should not be waited out

Most of these symptoms have innocent explanations. The point is not to panic but to get them investigated rather than watched:

• A cough that has lasted more than three weeks, or a long-standing smoker's cough that has changed in character
• Coughing up blood (haemoptysis), in any quantity, even once
• Unexplained weight loss
• Breathlessness that is gradually worsening
• Chest or shoulder pain that persists
• Hoarseness lasting beyond three weeks
• Repeated chest infections in the same part of the lung
• Fatigue that is out of proportion to activity
• A chest X-ray reported as abnormal, however vaguely

What actually finds lung cancer early

The chest X-ray is a starting point, not an answer: A normal chest X-ray does not rule out lung cancer, and an abnormal one rarely explains itself. Small lesions, lesions hidden behind the heart or diaphragm, and apical lesions are routinely missed. If there is genuine clinical suspicion, the next step is a CT — not a repeat X-ray in a month.

CT scan characterises the problem: A contrast CT of the chest shows the size, shape, margins and position of a lesion, and whether lymph nodes in the centre of the chest are enlarged. Crucially in India, old healed tuberculosis leaves calcified scars in the lung that look like nodules for the rest of a person's life. Comparing against any previous scan is often the single most useful thing that can be done, because a lesion unchanged over three years is almost never cancer.

PET-CT assesses activity and spread: Where a lesion is indeterminate or staging is required, PET-CT shows metabolic activity and identifies disease elsewhere in the body. It does not replace tissue diagnosis — inflammation and active TB can both light up on PET — but it guides where to sample and whether disease is localised.

Tissue is what gives the answer: No scan diagnoses cancer. A scan raises the question; tissue answers it. And in India, tissue answers a second question at the same time — whether this is cancer, tuberculosis, or both.

How EBUS-TBNA changed lung cancer diagnosis

For decades, sampling lymph nodes in the centre of the chest meant mediastinoscopy: a surgical procedure under general anaesthesia, with an incision at the base of the neck and a hospital stay.

EBUS-TBNA — endobronchial ultrasound with transbronchial needle aspiration — reaches the same structures through the natural airway, with no incision at all.

A thin flexible scope with an ultrasound probe at its tip is passed through the mouth into the main airways. The ultrasound looks through the airway wall at the lymph nodes and masses sitting behind it, and a fine needle is passed through the wall to take samples under direct ultrasound vision. It is done under conscious sedation, usually takes around 30 to 45 minutes, and most patients go home the same day.

• It samples multiple sites in one sitting: In a country where TB and lung cancer can coexist, sampling several lymph node stations rather than one reduces the chance of finding one disease and missing the other.
• It distinguishes TB from cancer definitively: The same sample can go for cytology, histology, TB culture and rapid molecular testing such as GeneXpert. One procedure, both questions answered.
• It stages accurately: Whether the cancer is confined to the lung or has reached the mediastinal nodes determines whether surgery with curative intent is possible.
• It provides enough tissue for molecular testing — which in India matters more than most patients realise.

Molecular testing: why an Indian diagnosis is different

If lung adenocarcinoma is confirmed, the tumour should be tested for specific genetic alterations. This is not an optional extra.

EGFR mutations are far more common in Indians than in Western populations. Where roughly 10 to 15 per cent of adenocarcinomas in Caucasian patients carry an EGFR mutation, Indian studies report figures between about 23 and 44 per cent. A multicentre Indian study of 500 adenocarcinoma patients found EGFR mutations in 33 per cent. ALK rearrangements were found in around 3 per cent of that cohort.

Why this matters: patients with an activating EGFR mutation respond very differently to targeted oral therapy than those without. In one Indian analysis, response to oral tyrosine kinase inhibitor therapy was 74 per cent in patients with an activating EGFR mutation, compared with 5 per cent in those without — with progression-free survival of around 10 months versus 2 months.

The Indian Council of Medical Research (ICMR) has launched a nationwide programme to provide biomarker testing for lung cancer free of cost across the country, specifically because these mutations are common here and targeted drugs have become more affordable.

What early detection could realistically look like in India

India does not currently have a national lung cancer screening programme, and the evidence needed to design one for this population is still being gathered. Researchers have been explicit that Western eligibility criteria cannot simply be transplanted here.

Until that exists, earlier detection depends on three unglamorous things:

• 1. Treating a persistent cough as a question, not a diagnosis: Three weeks is the threshold at which watching should stop and investigating should start.
• 2. Not accepting unconfirmed TB treatment indefinitely: If there is no microbiological or tissue confirmation and no clear improvement in four to six weeks, the diagnosis needs revisiting.
• 3. Getting tissue when imaging is suspicious, rather than repeating scans: Watchful waiting has a role for small, low-risk, stable nodules. It has no role when a lesion is growing, when nodes are enlarged, or when the clinical picture is concerning.

When to see a pulmonologist

Seek specialist assessment if you have:

• A cough persisting beyond three to four weeks without explanation
• Coughed up blood, even once
• Been on anti-TB treatment without confirmation and are not improving
• An abnormal chest X-ray or CT, including a nodule or mass
• Unexplained weight loss with any respiratory symptom
• Been advised lung surgery for a lesion that has not been biopsied
• A confirmed lung cancer diagnosis without molecular testing having been discussed